Use of this guideline in any setting must be subject to the clinical judgment of those responsible for providing care.



Document Scope: Hospital-wide Patient Care

Document Type: Clinical Practice Guideline

Approved on: January 2024 Next Review Date: January 2027

Acute Splenic Sequestration: Guidelines for Management in Children with Sickle Cell Disease (Adapted from the Hospital for Sick Children)

Version: 2

1.0 Background

Although the spleen does not properly perform its filtration function in patients with sickle cell disease, its reservoir function is overactive: sequestration of large quantities of blood (often half or more of a child's blood volume) can occur rapidly. This complication, termed acute splenic sequestration, is characterized by pooling of large quantities of sickled RBCs in the splenic red pulp, sudden enlargement of the spleen (within hours), and a precipitous decline in hemoglobin (Hb) and platelets, and an increase in reticulocytes.

Presentation is often (60%) associated with episodes of fever, suggesting an underlying viral etiology. Most commonly occurs in infants and young children between 6 months and 5 years of age with sickle cell anemia. It may also occur in older patients with any sickle cell phenotype with or without chronic splenomegaly. Often there is no obvious triggering event.

2.0 Clinical/Laboratory Features

A child with an acute splenic sequestration presents with symptoms of:

- acute anemia (pallor, tachycardia, frank cardiovascular collapse);
- splenomegaly/abdominal pain (pain in the left upper quadrant); and
- evidence of an active bone marrow response (increased reticulocytes) plus or minus thrombocytopenia.


Retrospective reviews have shown a first-episode mortality of as high as 14%. On physical examination, patients show signs of anemia, hypovolemia, and an enlarged spleen (larger than baseline), sometimes massively so. Mild cases may be asymptomatic.

Hemoglobin concentration is at least 20g/L below the baseline steady state. In severe cases, hemoglobin may decline to life-threatening levels. Reticulocyte counts are usually elevated, which distinguishes this condition from aplastic crisis. The platelet count often declines to <50 X 10⁹/L.

The mainstay of management is transfusion to provide circulating erythrocytes and volume. Risk of recurrence is approximately 40–50%, usually within 3 years. Because it is not possible to predict which children will have recurrent attacks, most experts recommend splenectomy after the first major attack (for patients >2 years old), or chronic transfusion to maintain a hemoglobin S level under 50% until the patient can get to surgery once all relevant immunizations have been completed.

Sickle Cell Disease Acute Splenic Sequestration

Use of this guideline in any setting must be subject to the clinical judgment of those responsible for providing care.



Inpatient Management

Admit to ward/transfer to IWK.

Cardiopulmonary monitoring.

YES

· Monitor vital signs.

NO

Consult IWK PICU.

- Repeat physical assessment:
 - Spleen size: q4-6h (measure with tape and record)
 - Hb q8-12h
- If hemoglobin is >20g/L below baseline, transfuse as soon as
 possible with cross matched PRBC not increasing Hb > 30 g/L of
 presenting Hb with initial transfusion. Transfuse in consultation with
 Hematology/Oncology. Use phenotypically matched blood. If
 unstable, give IV fluid bolus followed by PRBC.
- Continue regularly scheduled medications unless blood counts are low and hydroxyurea is required to be held.

Child discharged home from inpatient unit with appropriate follow-up if:

- Evidence of rising hemoglobin and diminishing spleen size.
- Blood count (Hb and platelet) should be monitored due to persistent splenomegaly & hypersplenism.
- Child has stable vital signs including afebrile unless a clear viral source.
- Tolerating fluids and medications by mouth.
- · Childs pain is controlled by oral analgesics.
- Determine risk for readmission (high risk: 3 admissions for VOC or 1 admission for ACS in the last 12 months).
- All patients at high risk for readmission must be seen in clinic within 14 days of discharge
- · Does not have respiratory distress; and
- Follow up confirmed within 2 weeks of discharge.

Sickle Cell Disease Acute Splenic Sequestration

Page 3 of 3

Use of this guideline in any setting must be subject to the clinical judgment of those responsible for providing care.

4.0 References

- 1. Emond AM, Collis F, Darvill D, et al. Acute splenic sequestration in homozygous sickle cell disease: natural history and management. *J Pediatr.* 1985;107(2):201–06.
- 2. National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease: Expert panel report, 2014.
- 3. Powell RW, Levine GL, Yang YM, et al. Acute splenic sequestration crisis in sickle cell disease: early detection and treatment. *J Pediatr Surg*. 1992;27(2):215–19.